NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: Oct 29 2025

0mins

Source: PRnewswire

Reverse Share Split Announcement: NLS Pharmaceutics Ltd. plans to implement a 1-for-10 reverse share split of its common shares, effective October 30, 2025, coinciding with its merger with Kadimastem Ltd.
New Trading Symbol and Name: Following the reverse split and merger, the company's shares will trade under the new symbol "NCEL" and the new name "NewcelX Ltd." starting October 31, 2025.
Share Capital Structure Post-Merger: After the reverse split and merger, the company will have approximately 4.56 million outstanding common shares and a revised capital structure, including preferred shares and participation certificates.
Fractional Shares and Adjustments: No fractional shares will be issued due to the reverse split; instead, cash will be provided for any resulting fractions, and all existing options and warrants will be adjusted accordingly.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like undefined with instant alerts to capture every critical market movement.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.